8 Best Cyclica Alternatives & Competitors (2026)

Exscientia combines generative AI and active learning to design novel compounds and operates its own clinical-stage programs. Compared with Numerion Labs, Exscientia places heavier emphasis on end-to-end automation from target to clinic and maintains a larger disclosed pipeline. Its enterprise collaborations often involve milestone payments rather than pure software licensing.

Insilico Medicine uses generative adversarial networks and reinforcement learning to create drug candidates, supported by its own therapeutic pipeline. Unlike Numerion Labs focus on exploring pre-existing chemical space, Insilico emphasizes de-novo generation. It offers both platform access and co-development partnerships, usually under subscription-plus-success-fee terms.

Atomwise applies deep learning to structure-based virtual screening across billions of compounds. Its strength lies in rapid hit finding for diverse targets, while Numerion Labs highlights molecules unseen by others through broader chemical-space mapping. Atomwise primarily operates via research collaborations rather than self-serve software.

BenevolentAI integrates knowledge graphs with generative models to surface novel drug candidates and runs internal programs. Relative to Numerion Labs, it covers a wider range of disease areas beyond immune indications and relies more on curated biomedical data. Access is typically granted through strategic partnerships.

Relay Therapeutics uses dynamic protein simulations and ML to drug motion-based targets, maintaining an internal pipeline. Its approach is more structure-dynamics focused than Numerion Labs chemical-space exploration. Pricing is not public; engagements occur via collaboration agreements.

Recursion leverages large-scale phenotypic screening and ML to map cellular biology and runs multiple clinical programs. Compared with Numerion Labs small-molecule focus, Recursion covers broader target classes and uses proprietary wet-lab data at massive scale. Collaborations follow milestone-driven models.